The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies

REFERENCES

• Adcock, C. J. (1997). Sample size determination: a review. Statistician 46(2):261–283.
   Google Scholar
• Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., Sledge, G. W., Winer, E. P., Hudis, C., Ingle, J. N., Perez, E. A., Pritchard, K. I., Shepherd, L., Gralow, J. R., Yoshizawa, C., Allred, D. C., Osborne, C. K., Hayes, D. F. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology 11(1):55–65.
   PubMed Web of Science ®Google Scholar
• Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., Chang, D. D. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26(10):1626–1634.
   PubMed Web of Science ®Google Scholar
• Barker, A. D., Sigman, C. C., Kelloff, G. J., Hylton, N. M., Berry, D. A., Esserman, L. J. (2009). I-spy 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics 86(1):97–100.
   PubMed Web of Science ®Google Scholar
• Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., Beck, J. T., Ito, Y., Yardley, D., Deleu, I., Perez, A., Bachelot, T., Vittori, L., Xu, Z., Mukhopadhyay, P., Lebwohl, D., Hortobagyi, G. N. (2011). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine 366(6):520–529.
   PubMed Web of Science ®Google Scholar
• Berry, D. A. (2005). Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis. Clinical Trials. 2(4):295–300; discussion 301–304, 364–378.
   PubMed Web of Science ®Google Scholar
• Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery 5(1):27–36.
   PubMed Web of Science ®Google Scholar
• Berry, S. M. (2011). Bayesian Adaptive Methods for Clinical Trials. Chapman & Hall/CRC bio-statistics series. Boca Raton: CRC Press.
   Google Scholar
• Bild, A. H., Parker, J. S., Gustafson, A. M., Acharya, C. R., Hoadley, K. A., Anders, C., Marcom, P. K., Carey, L. A., Potti, A., Nevins, J. R., Perou, C. M. (2009). An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Research 11(4):R55.
   PubMed Web of Science ®Google Scholar
• Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B., Phillips, W. A. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research 64(21):7678–7681.
   PubMed Web of Science ®Google Scholar
• Chen, M. H., Ibrahim, J. G., Lam, P., Yu, A., Zhang, Y. (2011). Bayesian design of noninferiority trials for medical devices using historical data. Biometrics 67(3):1163–1170.
   PubMed Web of Science ®Google Scholar
• Cheung, Y. K., Inoue, L. Y. T., Wathen, J. K., Thall, P. F. (2006). Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine 25(1):55–70.
   PubMed Web of Science ®Google Scholar
• DeCensi, A., Guerrieri-Gonzaga, A., Gandini, S., Serrano, D., Cazzaniga, M., Mora, S., Johansson, H., Lien, E. A., Pruneri, G., Viale, G., Bonanni, B. (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of Oncology 22(3):582–587.
   PubMed Web of Science ®Google Scholar
• Durham, S. D., Flournoy, N., Li, W. (1998). A sequential design for maximizing the probability of a favourable response. Canadian Journal of Statistics-Revue Canadienne De Statistique. 26(3):479–495.
   Web of Science ®Google Scholar
• Eisele, J. R., Woodroofe, M. B. (1995). Central limit-theorems for doubly adaptive biased coin designs. Annals of Statistics 23(1):234–254.
   Web of Science ®Google Scholar
• Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J. Q., DeSchryver, K., Allred, D. C., Esserman, L. J., Unzeitig, G. W., Margenthaler, J., Babiera, G. V., Marcom, P. K., Guenther, J. M., Watson, M. A., Leitch, M., Hunt, K., Olson, J. A. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. Journal of Clinical Oncology 29(17):2342–2349.
   PubMed Web of Science ®Google Scholar
• Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S., Nobel, A. B., van’t Veer, L. J., Perou, C. M. (2006). Concordance among gene-expression-based predictors for breast cancer. The New England Journal of Medicine 355(6):560–569.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., McShane, L. M., Korn, E. L. (2010). Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 102(3):152–160.
   PubMed Web of Science ®Google Scholar
• Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., Lander, E. S. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439):531–537.
   PubMed Web of Science ®Google Scholar
• Hamburg, M. A., Collins, F. S. (2010). The path to personalized medicine. The New England Journal of Medicine 363(4):301–304.
   PubMed Web of Science ®Google Scholar
• Hu, F. F., Zhang, L. X. (2004). Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials. Annals of Statistics 32(1):268–301.
   Web of Science ®Google Scholar
• Inoue, L. Y., Thall, P. F., Berry, D. A. (2002). Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58(4):823–831.
   PubMed Web of Science ®Google Scholar
• Ivanova, A. (2003). A play-the-winner-type urn design with reduced variability. Metrika 58(1):1–13.
   Web of Science ®Google Scholar
• Kass, R. E., Steffey, D. (1989). Approximate bayes-inference in conditionally independent hierarchical-models (parametric empirical bayes models). Journal of the American Statistical Association 84(407):717–726.
   Web of Science ®Google Scholar
• Kim, E. S., Herbst, R. S., Wistuba, I., Lee, J. J., Blumenschein, G. R., J., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., J., Gupta, S., Alden, C. M., Liu, S., Tang, X., Khuri, F. R., Tran, H. T., Johnson, B. E., Heymach, J. V., Mao, L., Fossella, F., Kies, M. S., Papadimitrakopoulou, V., Davis, S. E., Lippman, S. M., Hong, W. K. (2011). The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 1(1):44–53.
   PubMed Web of Science ®Google Scholar
• Lunn, D. J., Thomas, A., Best, N., Spiegelhalter, D. (2000). Winbugs – a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 10(4):325–337.
   Web of Science ®Google Scholar
• Mandrekar, S. J., Sargent, D. J. (2010). Randomized phase II trials: time for a new era in clinical trial design. Journal of Thoracic Oncology 5(7):932–934.
   PubMed Web of Science ®Google Scholar
• Markman, B., Atzori, F., Perez-Garcia, J., Tabernero, J., Baselga, J. (2010). Status of pi3k inhibition and biomarker development in cancer therapeutics. Annals of Oncology 21(4):683–691.
   PubMed Web of Science ®Google Scholar
• McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., Clark, G. M. (2005). Reporting recommendations for tumor marker prognostic studies (REMARK). Journal of the National Cancer Institute 97(16):1180–1184.
   PubMed Web of Science ®Google Scholar
• Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., Yasui, Y. (2001). Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 93(14):1054–1061.
   PubMed Web of Science ®Google Scholar
• Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., Botstein, D. (2000). Molecular portraits of human breast tumours. Nature 406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Plummer, M. (2008). JAGS Version 1.0.3 Manual. Lyon: IARC.
   Google Scholar
• Rosenberger, W. F. (1993). Asymptotic inference with response-adaptive treatment allocation designs. Annals of Statistics 21(4):2098–2107.
   Web of Science ®Google Scholar
• Rosenberger, W. F., Lachin, J. M. (2002). Randomization in Clinical Trials : Theory and Practice. Wiley series in probability and statistics. New York: Wiley.
   Google Scholar
• Rosenberger, W. F., Stallard, N., Ivanova, A., Harper, C. N., Ricks, M. L. (2001). Optimal adaptive designs for binary response trials. Biometrics 57(3):909–913.
   PubMed Web of Science ®Google Scholar
• Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2003). Her-2/neu testing in breast cancer. American Journal of Clinical Pathology 120 (Suppl):S53–71.
   PubMedGoogle Scholar
• Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., Smith, M. A. (2005). Design issues of randomized phase II trials and a proposal for phase II screening trials. Journal of Clinical Oncology 23(28):7199–7206.
   PubMed Web of Science ®Google Scholar
• Schmitt, M., Harbeck, N., Daidone, M. G., Brynner, N., Duffy, M. J., Foekens, J. A., Sweep, F. C. (2004). Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. International Journal of Oncology 25(5):1397–1406.
   PubMed Web of Science ®Google Scholar
• Simon, R. (1989). Optimal 2-stage designs for phase-II clinical-trials. Controlled Clinical Trials 10(1):1–10.
   PubMedGoogle Scholar
• Simon, R. M., Paik, S., Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute 101(21):1446–1452.
   PubMed Web of Science ®Google Scholar
• Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein Lonning, P., Borresen-Dale, A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98(19):10869–10874.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Abrams, K. R., Myles, J. P. (2004). Bayesian Approaches to Clinical trials and Health Care Evaluation. Statistics in practice. Hoboken, NJ: Wiley, Chichester.
   Google Scholar
• Spiegelhalter, D. J., Freedman, L. S. (1986). A predictive approach to selecting the size of a clinical-trial, based on subjective clinical opinion. Statistics in Medicine 5(1):1–13.
   PubMed Web of Science ®Google Scholar
• Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical-trials – conditional or predictive power. Controlled Clinical Trials 7(1):8–17.
   PubMedGoogle Scholar
• Spiegelhalter, D. J., Freedman, L. S., Parmar, M. K. B. (1994). Bayesian approaches to randomized trials. Journal of the Royal Statistical Society: Series A (Statistics in Society) 157:357–387.
   Web of Science ®Google Scholar
• Thall, P. F., Wathen, J. K., Bekele, B. N., Champlin, R. E., Baker, L. H., Benjamin, R. S. (2003). Hierarchical bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine 22(5):763–780.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nature Reviews Molecular Cell Biology 11(5):329–341.
   PubMed Web of Science ®Google Scholar
• Vogelstein, B., Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature Medicine 10(8):789–799.
   PubMed Web of Science ®Google Scholar
• Wei, L. J., Durham, S. (1978). Randomized play-winner rule in medical trials. Journal of the American Statistical Association 73(364):840–843.
   Web of Science ®Google Scholar
• Zelen, M. (1969). Play winner rule and controlled clinical trial. Journal of the American Statistical Association 64(325):131.
   Web of Science ®Google Scholar
• Zhou, X., Liu, S. Y., Kim, E. S., Herbst, R. S., Lee, J. L. (2008). Bayesian adaptive design for targeted therapy development in lung cancer – a step toward personalized medicine. Clinical Trials 5(3):181–193.
   PubMed Web of Science ®Google Scholar